Topics

Nicotinamide Riboside in Hospitalized Patients

2019-10-04 08:31:35 | BioPortfolio

Summary

Patients will receive oral nicotinamide riboside or placebo and clinical and paraclinical outcome will be determined

Description

Patients experiencing acute illness will often have a prolonged recovery time. The cause of this is unknown, but certain factors, like age, duration, and graveness of the illness, is associated with prolonged recovery. In this study, we will investigate whether nicotinamide riboside can shorten the recovery phase and improve outcome after acute illness.

Study Design

Conditions

Inflammation

Intervention

Nicotinamide riboside, Placebo

Location

Oslo University Hospital
Oslo
Norway
0450

Status

Recruiting

Source

Oslo University Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-10-04T08:31:35-0400

Clinical Trials [771 Associated Clinical Trials listed on BioPortfolio]

Assessment of Brain NAD+ in College Football Players Taking Nicotinamide Riboside vs Controls

Can nicotinamide riboside (750 mg/day for 12 weeks) affect the levels of NAD+ in the brain as measured by 31P MRS?

Effects of Nicotinamide Riboside on Metabolism and Vascular Function

The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplementation on metabolism and vascular function following high-fat meal. Differences between young (...

A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study

NOPARK is a double-blinded randomized controlled trial that studies nicotinamide supplementation in early Parkinson's disease. Parkinson's disease (PD) is a major cause of death and disab...

Nicotinamide Riboside in Systolic Heart Failure

Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to oxidi...

Nicotinamide Riboside and Metabolic Health

This study will investigate the effects of 6 week Nicotinamide Riboside supplementation (1000 mg/day) on metabolic health in healthy (pre)obese humans. The primary objective will be hepati...

PubMed Articles [5049 Associated PubMed Articles listed on BioPortfolio]

NAD repletion inhibits the endothelial-to-mesenchymal transition induced by TGF-β in endothelial cells through improving mitochondrial unfolded protein response.

Endothelial-to-mesenchymal transition (EndMT) plays an important role in the progression of cardiac fibrosis but its mechanism and treatment need to be further understood. Herein, we have found that m...

Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures.

Nicotinamide adenine dinucleotide (NAD) is modulated by conditions of metabolic stress and has been reported to decline with aging in preclinical models, but human data are sparse. Nicotinamide ribosi...

Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis.

Liver fibrosis is part of the non-alcoholic fatty liver disease (NAFLD) spectrum, which currently has no approved pharmacological treatment. In this study, we investigated whether supplementation of n...

Effects of nicotinamide riboside on endocrine pancreatic function and incretin hormones in obese, non-diabetic men.

Augmenting NAD+ metabolism through dietary provision of NAD+ precursor vitamins translate to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the ...

Endogenous nicotinamide riboside metabolism protects against diet-induced liver damage.

Supplementation with the NAD precursor nicotinamide riboside (NR) ameliorates and prevents a broad array of metabolic and aging disorders in mice. However, little is known about the physiological role...

Medical and Biotech [MESH] Definitions

An enzyme that catalyzes the formation of nicotinamide mononucleotide (NMN) from nicotinamide and 5-phosphoribosyl-1-pyrophosphate, the rate-limiting step in the biosynthesis of the NAD coenzyme. It is also known as a growth factor for early B-LYMPHOCYTES, or an ADIPOKINE with insulin-mimetic effects (visfatin).

3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5'phosphate, inner salt. A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN.

An enzyme that catalyzes the hydrolysis of nicotinamide adenine dinucleotide (NAD) to NICOTINAMIDE and ADENOSINE DIPHOSPHATE RIBOSE. Some are extracellular (ectoenzymes).The enzyme from some sources also catalyses the hydrolysis of nicotinamide adenine dinucleotide phosphate (NADP).

An enzyme found primarily in the LIVER that catalyzes the N-methylation of NICOTINAMIDE and other structurally related compounds.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

More From BioPortfolio on "Nicotinamide Riboside in Hospitalized Patients"

Quick Search

Searches Linking to this Trial